Unfortunately, a substantial number of patients do not respond to anti-PD-1/PD-L1 therapy, often patients with low levels of tumor-infiltrating CD8+ T cells and no signs of T cell activation [12, 13]. This evidence concerns the gene CD8A and neoplasm.